已收盤 07-31 16:00:00 美东时间
0.000
0.00%
Abivax SA issued a statement addressing a report by Scorpion Capital, which the company claims contains factually inaccurate and misleading statements. Abivax emphasizes the integrity of its clinical data, particularly from its Phase 3 ABTECT trials, and plans to file an NDA with the U.S. FDA by year-end. Scorpion Capital disclosed a short position in Abivax, highlighting its financial incentive to lower the company's share price. Abivax is a cli...
11-20 21:33
Abivax press release (ABVX): 1H The Company had cash, cash equivalents and short-term investments of €402.4 million as of June 30, 2026. More on Abivax Abivax: Obefazimod Goes The Distance And So Does...
09-22 04:09
Abivax (ABVX) said the underwriters of its U.S. public offering have fully exercised their option to purchase an additional 960K American Depositary Shares (ADSs). With the overallotment option fully ...
07-02 19:06
Abivax SA (ABVX) priced an upsized public offering of 6.4M ADSs at $125/ADS, raising ~$800M in gross proceeds. The offering size was increased from the previously announced $600M. The company granted ...
07-01 20:56
Abivax SA (ABVX) on Tuesday announced the launch of an underwritten public offering of ~$600M of its American Depositary Shares, each representing one ordinary share of Abivax, nominal value €0.01 per...
07-01 05:02
Abivax SA (ABVX) shares surged Tuesday premarket after the biotech reported positive topline supplemental data from its Phase 3 ulcerative colitis maintenance program, delivering strong efficacy while...
06-30 15:49
Abivax's Phase 3 ulcerative colitis data met remission goals, but cancer cases in the study raised safety questions and analyst caution.
06-04 22:35
Abivax shares plunge more than 35% as cancer cases reported in a Phase 3 trial overshadow strong efficacy results for ulcerative colitis drug.
06-02 20:49
HPE: 30% | Hewlett Packard Enterprise shares are trading higher after the company reported better-than-expected Q2 financial results BJDX: 200% | Bluejay Diagnostics Announces Strategic Partnership With
06-02 19:24
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative ColitisAt Week 44, both the 25 mg and 50 mg once-daily obefazimod doses met the primary
06-02 04:08